Intellia Therapeutics, Inc. 8-K

What Happened Intellia Therapeutics, Inc. (NTLA) announced that its Board adopted Fourth Amended and Restated By‑laws, effective April 7, 2026. The Amended By‑laws add a procedure allowing shareholders to cure facially apparent deficiencies in a timely notice of a nomination or proposal and require the company to notify shareholders of any such facially apparent deficiencies. The Amended By‑laws also designate the federal district courts of the United States as the exclusive forum for claims arising under the Securities Act of 1933 or the Securities Exchange Act of 1934, unless the company agrees in writing to a different forum.

Key Details

• Effective date: April 7, 2026.
• New cure provision: shareholders may correct "facially apparent" defects in timely notices of nominations or proposals; the company must notify shareholders of those defects.
• Exclusive forum: federal district courts designated as exclusive forum for causes of action under the Securities Act and Exchange Act, unless the company consents otherwise.

Why It Matters These bylaw changes affect how shareholder proposals and nominations are handled and where securities‑law disputes must be litigated. The cure provision can help shareholders preserve their ability to submit nominations or proposals if their initial notice has an obvious defect. The exclusive‑forum provision centralizes securities‑law claims in federal district courts rather than state courts, which can affect litigation strategy and predictability for both the company and shareholders.